spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  TNF 

 HSMN NewsFeed - 10 Feb 2025
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 23 Sep 2024
UCB Announces U.S. FDA Approvals for BIMZELX(R) (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Jul 2024
HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 May 2022
Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 14 Apr 2022
NCCN Guidelines(R) Recommend VONJO(TM) (pacritinib) for the Treatment of Myeloproliferative Neoplasms
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Dec 2021
Sorriso Pharmaceuticals Launches with $31 Million to Develop Novel Class of Orally Delivered Cytokine Antibodies to Treat Inflammatory Conditions
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 30 Sep 2021
OLUMIANT(R) Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata
Biopharmaceuticals
 HSMN NewsFeed - 6 Aug 2021
BioInvent Announces Second Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1808 in Combination with KEYTRUDA(R) (pembrolizumab) in Patients with Advanced Solid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2021
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 20 Apr 2021
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
Biopharmaceuticals
 HSMN NewsFeed - 11 Dec 2020
CHMP Recommends the Approvals of RINVOQ(TM) (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Nov 2020
Innovent Announces NMPA Granted New Indication Approval for SULINNO(R) (Adalimumab Injection) in China for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Sep 2020
CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 3 Sep 2020
Innovent Announces NMPA Granted Marketing Approval for SULINNO(R) (Adalimumab Injection) in China
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Jul 2020
FDA Clears Abivertinib for Phase 2 Safety and Efficacy Study in Hospitalized Patients with Moderate To Severe Covid-19
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Jul 2020
TREMFYA(R) (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Jun 2020
Mylan and Lupin Receive European Marketing Authorization for Nepexto(R), Biosimilar Etanercept
Biopharmaceuticals Generics Regulatory
 HSMN NewsFeed - 1 Jun 2020
Lilly's Taltz(R) (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Mar 2020
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Feb 2020
KAHR Medical Raises $18 Million in Private Funding Round
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 21 Nov 2019
Araim Pharmaceuticals Selects Ferry Breedveld as Acting CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Nov 2019
ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz(R) (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
Biopharmaceuticals
 HSMN NewsFeed - 18 Oct 2019
AbbVie Receives CHMP Positive Opinion for Upadacitinib (RINVOQ(TM)) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Aug 2019
Lilly Receives U.S. FDA Approval for Taltz(R) (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Jul 2019
U.S. CPT Code Granted for KidneyIntelX(TM)
Diagnostics Reimbursement
 HSMN NewsFeed - 14 Jun 2019
Janssen reports top-line Phase 3 results for TREMFYA(R) (guselkumab) in adults with active psoriatic arthritis
Biopharmaceuticals
 HSMN NewsFeed - 2 May 2019
FDA Grants Breakthrough Device Designation to KidneyIntelX(TM)
Diagnostics FDA
 HSMN NewsFeed - 13 Mar 2019
Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA(R)
Biopharmaceuticals Generics Dermatology
 HSMN NewsFeed - 19 Feb 2019
AbbVie Announces New Drug Application Accepted for Priority Review by U.S. FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Jan 2019
Oculis Expands Portfolio with the In-Licensing of a Novel Phase II-stage Anti-TNF Alpha Antibody Fragment
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 4 Jan 2019
Oculis Raises CHF15.5 Million in an Extension of its Series B Financing Round - Total Raised CHF35.5 Million
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 13 Dec 2018
FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Sep 2018
AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 23 Jul 2018
Sangamo Therapeutics to Acquire TxCell
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 28 Jun 2018
Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients
Biopharmaceuticals
 HSMN NewsFeed - 28 Jun 2018
Lupin and Mylan Partner to Commercialize Enbrel(R) (Etanercept) Biosimilar
Biopharmaceuticals Generics
 HSMN NewsFeed - 29 May 2018
UCB Announces the Approval of CIMZIA(R) (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 13 Feb 2018
Lilly Announces Positive Top-Line Phase 3 Results for Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Biopharmaceuticals
 HSMN NewsFeed - 4 Jan 2018
Enterome Raises €32 Million ($38.5 Million) in a Series D Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 12 Dec 2017
Eyevensys Appoints Dr. Patricia Zilliox as Chief Executive Officer
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 29 Nov 2017
Aethlon Medical Names Dr. Charles J. Fisher Chairman of the Board
Devices Personnel
 HSMN NewsFeed - 17 Nov 2017
Amgen Launches The ENBREL Mini(TM) Single-Dose Prefilled Cartridge With AutoTouch(TM) Reusable Autoinjector That Is Ergonomically Designed For Patients
Biopharmaceuticals Devices Drug Delivery Product Launch
 HSMN NewsFeed - 8 Nov 2017
Long-Term Use of Lilly's Taltz(R) (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors
Biopharmaceuticals
 HSMN NewsFeed - 28 Sep 2017
AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Amgen
Biopharmaceuticals Generics Litigation Licensing
 HSMN NewsFeed - 4 Sep 2017
Eyevensys Appoints Dr Ronald R. Buggage as Chief Medical Officer
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 16 Jun 2017
New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017
Biopharmaceuticals
 HSMN NewsFeed - 14 Apr 2017
U.S. FDA Issues Complete Response Letter for Baricitinib
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Mar 2017
U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA(R) (adalimumab) Prescribing Information
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Mar 2017
Eyevensys Appoints Leading Life Sciences Executive and Ophthalmology Expert Dr. Garth Cumberlidge as Chairman
Biopharmaceuticals Devices Ophthalmology Personnel
 HSMN NewsFeed - 28 Feb 2017
Kevzara(TM) (sarilumab) now available in Canada for the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 14 Feb 2017
European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Feb 2017
AAVP Biosystems Hires Mark Shapiro, M.D., Ph.D. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Dec 2016
Janssen Submits Application Seeking FDA Approval of STELARA(R) (Ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 14 Dec 2016
Health Canada approves STELARA(R) for the treatment of adults with moderately to severely active Crohn's disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 14 Nov 2016
AbbVie's HUMIRA(R) (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 22 Sep 2016
aTyr Pharma Appoints Industry Veteran in Novel Biology Biologics, David J. King, PhD, as Senior Vice President, Research
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Sep 2016
Eyevensys Announces Series A Extension Bringing Total Capital Raised to €9 Million
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 8 Aug 2016
Araim Pharmaceuticals Announces Appointment of Ferdinand C. Breedveld, M.D. as Chairman of the Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 May 2016
FLIXABI(R), Biogen’s Infliximab Biosimilar Referencing Remicade(R), Approved in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 May 2016
AbbVie's HUMIRA(R) (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 27 Apr 2016
Novartis Receives Three FDA Breakthrough Therapy Designations for IlaristTo Treat Rare Types of Periodic Fever Syndromes
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Apr 2016
Pfizer Announces Positive Top-Line Results from the First Phase 3 Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 4 Apr 2016
AbbVie Receives CHMP Positive Opinion for HUMIRA(R) (adalimumab) for the Treatment of Pediatric Patients, from Six Years of Age, with Moderately to Severely Active Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 18 Mar 2016
STELARA(R) Induced Clinical Response And Remission In Phase 3 Study For The Treatment Of Patients With Moderate To Severe Crohn's Disease Who Had Previously Failed Or Were Intolerant To Anti-TNF-Alpha Therapy
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 2 Mar 2016
Merck KGaA, Darmstadt, Germany Initiates Phase III Study of MSB11022, a Proposed Biosimilar of Adalimumab, in Chronic Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 17 Jan 2016
BENEPALI(R), the First Etanercept Biosimilar Referencing Enbrel(R), Approved in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 16 Jan 2016
Novartis receives two new FDA approvals for Cosentyx(R) (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Jan 2016
AbbVie's HUMIRA(R) (Adalimumab) Receives First and Only Health Canada Approval for Moderate to Severe Hidradenitis Suppurativa
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 4 Dec 2015
Samsung Bioepis' RENFLEXIS(R) Infliximab Biosimilar Receives Regulatory Approval in Korea
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 4 Dec 2015
Amgen's First Biosimilar Marketing Authorization Application Submitted To European Medicines Agency For ABP 501
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Nov 2015
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Sep 2015
AbbVie's HUMIRA(R) (Adalimumab) Receives First and Only U.S. Food and Drug Administration Approval for Moderate to Severe Hidradenitis Suppurativa
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 21 May 2015
Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 9 Dec 2014
Zydus Launches World's First Biosimilar of Adalimumab
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 19 Nov 2014
Crescendo Bioscience Highlights New Clinical Data on Vectra(R) DA at ACR
Diagnostics
 HSMN NewsFeed - 15 Oct 2014
Selecta Announces More than $20 Million in Equity Funding
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 27 Jun 2014
Protalix Announces New Data on ELELYSO(TM) (taliglucerase alfa) Presented at the European Working Group on Gaucher Disease 2014 11th Meeting
Biopharmaceuticals
 HSMN NewsFeed - 5 Mar 2014
Heat Biologics, Inc. Appoints Taylor H. Schreiber, M.D., PH.D. as Vice President of Research and Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Feb 2014
InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF)
Biopharmaceuticals
 HSMN NewsFeed - 17 Dec 2013
Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF Biosimilar Product Candidates in Europe
Biopharmaceuticals
 HSMN NewsFeed - 9 Dec 2013
FDA Advisory Committee Recommends Approval of Takeda's Investigational Biologic Vedolizumab
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Sep 2013
Cimzia(R) (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Sep 2013
Biomed Pharmaceuticals Announces Key Additions to Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Aug 2013
ChemoCentryx Announces GlaxoSmithKline's Release of Top-Line Results From the SHIELD-1 Phase III Study of Vercirnon
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 15 May 2013
Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
Biopharmaceuticals
 HSMN NewsFeed - 10 May 2013
Novartis drug Ilaris(R) approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
Biopharmaceuticals. FDA
 HSMN NewsFeed - 29 Apr 2013
UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 15 Apr 2013
Covagen Names Elias Papatheodorou Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Mar 2013
XELJANZ(R) (tofacitinib citrate) Approved in Japan for the Treatment of Adults with Rheumatoid Arthritis (RA)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Dec 2012
Avaxia Biologics Raises $6.4 Million in Series B Financing
Biopharmaceuticals Gastroenterology Venture Capital
 HSMN NewsFeed - 6 Dec 2012
Protalix BioTherapeutics Signs Clinical Development Agreement With Pfizer for ELELYSO(TM) (taliglucerase alfa)
Biopharmaceuticals
 HSMN NewsFeed - 12 Nov 2012
Abbott Announces First Long-term Patient-reported Health Outcomes Data for Investigational Use of HUMIRA(R) (Adalimumab) in Patients with Active Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Biopharmaceuticals
 HSMN NewsFeed - 7 Nov 2012
U.S. Food and Drug Administration Approves Pfizer’s XELJANZ(R) (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Methotrexate
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Oct 2012
Abbott Announces Three-Year Long-Term Data Evaluating Efficacy with HUMIRA(R) (Adalimumab) For Patients with Moderately to Severely Active Ulcerative Colitis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 31 Jul 2012
Prometheus Launches New Monitoring Test To Help Guide Inflammatory Bowel Disease Management
Diagnostics Personalized Medicine Gastroenterology
 HSMN NewsFeed - 27 Jul 2012
Genentech Reports Second Positive Study of ACTEMRA(R) Given by Subcutaneous Injection to Patients with Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 19 Jun 2012
AstraZeneca And Rigel Sign Worldwide License Agreement For A Potential New Treatment For Chronic Asthma
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 6 Jun 2012
Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA(R) (Adalimumab) in Patients with Active Peripheral Spondyloarthritis
Biopharmaceuticals
 HSMN NewsFeed - 6 Jun 2012
Abbott Announces 10-Year Data Evaluating HUMIRA(R) (Adalimumab) for Patients with Long-Standing Moderate-to-Severe Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 6 Jun 2012
Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA(R) (Adalimumab) in Patients with Active Non-radiographic Axial Spondyloarthritis
Biopharmaceuticals
 HSMN NewsFeed - 6 Jun 2012
ORENCIA(R) (abatacept) Demonstrates Comparable Efficacy to Humira(R) (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents
Biopharmaceuticals
 HSMN NewsFeed - 11 May 2012
Takeda Announces GEMINI II Trial of Vedolizumab in Patients with Moderately to Severely Active Crohn’s Disease Met Primary Endpoints of Improvement in Clinical Remission in Induction and Maintenance Phases
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 3 May 2012
Genentech Reports Positive Study of ACTEMRA Given by Subcutaneous Injection
Biopharmaceuticals
 HSMN NewsFeed - 2 Mar 2012
Genentech’s ACTEMRA(R) Monotherapy Showed Superior Improvement in Rheumatoid Arthritis Signs and Symptoms Versus Adalimumab Monotherapy
Biopharmaceuticals
 HSMN NewsFeed - 20 Jan 2012
Remicade(R) (Infliximab) Receives Positive Opinion From CHMP In Europe for Treatment of Ulcerative Colitis in Pediatric Patients
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 8 Nov 2011
Abbott Reports Five-Year Data for HUMIRA(R) (Adalimumab) in Ankylosing Spondylitis
Biopharmaceuticals
 HSMN NewsFeed - 7 Nov 2011
Abbott Presents HUMIRA(R) (Adalimumab) Phase 3 Study Results for Patients with Active Non-Radiographic Axial Spondyloarthritis
Biopharmaceuticals
 HSMN NewsFeed - 2 Nov 2011
Abbott to Present Broad Spectrum of Compelling Data for HUMIRA(R) (Adalimumab) at American College of Rheumatology Annual Scientific Meeting
Biopharmaceuticals
 HSMN NewsFeed - 12 Sep 2011
InterMune Announces Launch of Esbriet(R) (pirfenidone) in Germany
Biopharmaceuticals
 HSMN NewsFeed - 8 Sep 2011
Pfizer Announces Detailed Pivotal Data for Investigational Compound Tofacitinib in Rheumatoid Arthritis to be Presented at American College of Rheumatology 2011 Annual Scientific Meeting
Biopharmaceuticals
 HSMN NewsFeed - 10 May 2011
Abbott's HUMIRA(R) (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 28 Apr 2011
Pfizer Announces Top-Line Results Of Final Two Pivotal Phase 3 Trials Of Tofacitinib (CP-690,550) In Patients With Active Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 19 Apr 2011
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Apr 2011
FDA Approves ACTEMRA(R) (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Mar 2011
InterMune Receives European Union Approval for Esbriet(R) (pirfenidone)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 25 Feb 2011
FDA Issues Complete Response Letter for Taliglucerase Alfa New Drug Application
Biopharmaceuticals
 HSMN NewsFeed - 23 Feb 2011
Court of Appeals Overturns $1.8 Billion Patent Verdict for Centocor Ortho Biotech Inc.
Biopharmaceuticals Litigation
 HSMN NewsFeed - 5 Jan 2011
FDA Grants Supplemental Approval for ACTEMRA(R) (tocilizumab)
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Jan 2011
TetraLogic Closes $23 Million Second Tranche of Series C Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 8 Nov 2010
New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE(R) After Inadequate Response to Enbrel(R) or Humira(R) Demonstrate Marked Clinical Improvement
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2010
New Magnetic Resonance Imaging (MRI) Data Show Efficacy of SIMPONI(R) in Treatment of Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 27 Sep 2010
Centocor Ortho Biotech Inc. Submits Application to FDA Seeking to Expand SIMPONI(R) Label in Treatment of Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jul 2010
GTC Biotherapeutics Regains US Rights to ATryn(R) ; the First Recombinant Antithrombin Product Approved in the World
Biopharmaceuticals
 HSMN NewsFeed - 7 Jul 2010
European Commission Approves ORENCIA in Combination with Methotrexate for Earlier Use as First-Line Biologic after DMARD Inadequate Response for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 16 Jun 2010
GTC Biotherapeutics Announces New $7 Million Financing, Company Restructuring and Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 May 2010
GenVec Announces Resignation of Mark Thornton as Senior Vice President, Product Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 May 2010
Roche and Biogen Idec Announce Their Decision to Discontinue the ocrelizumab Clinical Development Programme in Patients with Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 15 Apr 2010
REMICADE(R) Study Results Show Greater Steroid-Free Remission and Mucosal Healing Compared With Conventional Immunomodulator Azathioprine in Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 16 Mar 2010
Genentech Submits Supplemental Biologics License Application for ACTEMRA(R) (tocilizumab) for Prevention of Structural Joint Damage and Improvement of Physical Function in Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Feb 2010
AstraZeneca and Rigel Pharmaceuticals Sign Worldwide License Agreement for Late-Stage Development Product -- Fostamatinib Disodium (R788) -- for the Treatment of Rheumatoid Arthritis (RA)
Biopharmaceuticals Licensing
 HSMN NewsFeed - 9 Jan 2010
FDA Approves ACTEMRA(R) (tocilizumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Dec 2009
Phase III Data Showed Rituxan Plus Chemotherapy Improved Survival in Patients With Most Common Form of Adult Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Oct 2009
New Data Presented From WELCOME Trial Show Positive Impact of CIMZIA(R) (certolizumab pegol) on Hospitalizations and Surgeries in Patients With Prior Infliximab Failure
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 26 Oct 2009
Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 20 Oct 2009
New Data Describe Safety of Subcutaneous Administration of ORENCIA(R) (abatacept) For Patients with Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 14 Oct 2009
XOMA Appoints Susan Kramer, Dr. P.H. Vice President of Project and Alliance Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Oct 2009
SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 Sep 2009
Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Aug 2009
Updated ORENCIA(R) (abatacept) Labeling Includes Data to Support Earlier Use in Adult Patients with Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 8 Jul 2009
Allostera Pharma Inc. Closes $17M (CAD) Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 26 Jun 2009
SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 4 Jun 2009
Enbrel(R) Receives Positive European Recommendations for a New Plaque Psoriasis Treatment Regimen and New Pre-Filled Pen Delivery Device
Biopharmaceuticals Drug Delivery Devices Regulatory
 HSMN NewsFeed - 1 Jun 2009
Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 13 May 2009
UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Apr 2009
SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Mar 2009
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 27 Feb 2009
Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 9 Feb 2009
MS Patients Treated with TYSABRI Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Jan 2009
GenVec Reduces Costs to Preserve Capital
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jan 2009
Cephalon Signs Option Agreement to Acquire Ception Therapeutics
Biopharmaceuticals
 HSMN NewsFeed - 6 Dec 2008
Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Dec 2008
Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)
Biopharmaceuticals
 HSMN NewsFeed - 21 Nov 2008
CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Nov 2008
GenVec Announces Interim Survival Data in Pivotal Trial of TNFerade in Locally Advanced Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Nov 2008
TNFerade(TM) Receives FDA Fast Track Designation for Treatment of Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Oct 2008
One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
Biopharmaceuticals
 HSMN NewsFeed - 27 Oct 2008
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
Biopharmaceuticals
 HSMN NewsFeed - 27 Oct 2008
Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 27 Oct 2008
New Study Shows ENBREL(R) (etanercept) Is More Effective than a DMARD in the Treatment of Symptoms of Ankylosing Spondylitis Patients
Biopharmaceuticals
 HSMN NewsFeed - 21 Oct 2008
Abbott's HUMIRA(R) (adalimumab) Data Shows Fistula Healing for Up to Three Years in Patients with Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 6 Oct 2008
CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 18 Sep 2008
Enbrel(R) Shown to Deliver Long-Lasting Improvements in Psoriasis Patients' Quality of Life
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 18 Sep 2008
Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 5 Sep 2008
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Sep 2008
Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
Biopharmaceuticals
 HSMN NewsFeed - 7 Aug 2008
ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 22 Jul 2008
Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 9 Jul 2008
European Commission Announces Marketing Authorisation for 50mg Once Weekly Enbrel(R) for Patients With Moderate-to-Severe Psoriasis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Jun 2008
Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals
 HSMN NewsFeed - 24 Jun 2008
NICE Recommends Abbott's Adalimumab (HUMIRA(R)) for the Treatment of Chronic Plaque Psoriasis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 18 Jun 2008
Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 13 Jun 2008
ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
Biopharmaceuticals
 HSMN NewsFeed - 13 Jun 2008
Data Show that Abbott's HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years
Biopharmaceuticals
 HSMN NewsFeed - 13 Jun 2008
HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity
Biopharmaceuticals
 HSMN NewsFeed - 13 Jun 2008
New Long-Term HUMIRA(R) (adalimumab) Data Show Up to Seven-Year Efficacy with Combination Treatment for Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 12 Jun 2008
ORENCIA(R) (abatacept) Provided an Increasing Degree of Inhibition of Structural Damage Through Three Years in Adults with Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 12 Jun 2008
New Data Demonstrates Joint Damage is Inhibited With Wyeth's Biologic Enbrel(R) Plus Methotrexate in Patients With Early Active Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 11 Jun 2008
Phase 3 Data Show Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Previously Treated with Anti-TNF Agents
Biopharmaceuticals
 HSMN NewsFeed - 11 Jun 2008
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jun 2008
Otsuka and UCB agreed to co-develop and co-promote Keppra(R) and Cimzia(R) in Japan
Biopharmaceuticals
 HSMN NewsFeed - 4 Jun 2008
Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2008
New Evidence Advocates the use of Enbrel to Combat and Effectively Control the Debilitating Symptoms of Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 21 May 2008
Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 21 May 2008
American Academy of Dermatology Issues New Guidelines for the Management of Psoriasis and Psoriatic Arthritis
Dermatology
 HSMN NewsFeed - 20 May 2008
Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 29 Apr 2008
Genentech and Biogen Idec Announce Top-Line Results from Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 23 Apr 2008
FDA Approval of Cimzia(R) for Crohn's Disease Represents Latest Milestone for Nektar's PEGylation Technology Platform
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 22 Apr 2008
Cimzia(R) Approved in the US for the Treatment of Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 16 Apr 2008
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 15 Apr 2008
Biogen Idec and Elan Present New TYSABRI(R) Data at the 60th Annual Meeting of the American Academy of Neurology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 8 Apr 2008
U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Mar 2008
Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 Mar 2008
Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)
Biopharmaceuticals
 HSMN NewsFeed - 17 Mar 2008
Data Presented at International Psoriasis Meeting Support Potential New Role for Biologic Treatment Etanercept in Management of Childhood Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 4 Mar 2008
UCB: Early Data on Cimzia(R) from the WELCOME Study Show Efficacy in Infliximab-Refractory Crohn's Disease Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 22 Feb 2008
Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Feb 2008
VLST Corporation Announces Board and Executive Management Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Feb 2008
FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Feb 2008
MediciNova's MN-166 Reduces Persistent Black Hole Formation in Multiple Sclerosis Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 25 Jan 2008
Genentech and Biogen Idec Announce Positive Results from a Phase III Trial of Rituxan in Patients with Rheumatoid Arthritis Who Inadequately Responded to Methotrexate
Biopharmaceuticals
 HSMN NewsFeed - 19 Jan 2008
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jan 2008
New Study Shows Biologic Therapy Enbrel(R) (etanercept) Effective in Treating Psoriasis in Children and Adolescents
Biopharmaceuticals
 HSMN NewsFeed - 16 Jan 2008
New Study Reports Enbrel(R) (Etanercept) Significantly Improved Moderate to Severe Plaque Psoriasis in Children and Adolescents
Biopharmaceuticals
 HSMN NewsFeed - 15 Jan 2008
Medivation Names Rohan Palekar Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jan 2008
FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease
Biopharmaceuticals FDA Gastroenterology
 HSMN NewsFeed - 8 Jan 2008
Anthera Pharmaceuticals Acquires the Worldwide Rights to a BAFF Inhibitor for the Treatment of Lupus and Other Autoimmune Diseases
Biopharmaceuticals Licensing
 HSMN NewsFeed - 21 Dec 2007
Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
Biopharmaceuticals Distribution
 HSMN NewsFeed - 20 Dec 2007
Abbott's HUMIRA(R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Dec 2007
Hollis-Eden Pharmaceuticals Announces Cystic Fibrosis Foundation Therapeutics Selects TRIOLEX(TM) (HE3286) as a Next-Generation Oral Anti-Inflammatory Drug Candidate
Biopharmaceuticals
 HSMN NewsFeed - 10 Dec 2007
Osiris Therapeutics Reports Positive Results for Prochymal(TM) as a Rescue Agent in Pediatric Patients with End-Stage Graft vs. Host Disease
Regenerative Medicine
 HSMN NewsFeed - 26 Nov 2007
InterMune Buys Out License Agreement for Pirfenidone
Biopharmaceuticals Licensing
 HSMN NewsFeed - 21 Nov 2007
Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 20 Nov 2007
Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
Biopharmaceuticals
 HSMN NewsFeed - 19 Nov 2007
Meyer Pharmaceuticals Acquires NF-kappaB Decoy Technology for Treatment of Inflammatory Disease
Biopharmaceuticals Dermatology Licensing
 HSMN NewsFeed - 16 Nov 2007
Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 16 Nov 2007
UCB to Appeal European Negative Opinion on CIMZIA(R) for the Treatment of Patients with Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 9 Nov 2007
Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2007
Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab)
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2007
Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2007
New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms Of Ankylosing Spondylitis According to Phase 3 Study Findings
Biopharmaceuticals
 HSMN NewsFeed - 6 Nov 2007
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
Biopharmaceuticals
 HSMN NewsFeed - 6 Nov 2007
Can-Fite: CF101 May Be Effective for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 15 Oct 2007
Clinical Studies Show REMICADE Reduces Incidence of Bowel Surgeries in Ulcerative Colitis Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 15 Oct 2007
Elan and Biogen Idec Announce That FDA Will Extend Regulatory Review Period for TYSABRI(R) for Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 1 Oct 2007
Axcan Licenses Rights to Cx401, an Innovative Biological Product in Development for the Treatment of Perianal Fistulas, a Significant Unmet Medical Need
Biopharmaceuticals Regenerative Medicine
 HSMN NewsFeed - 13 Aug 2007
Avigen Initiates U.S. Clinical Development for AV411
Biopharmaceuticals
 HSMN NewsFeed - 7 Aug 2007
ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Jul 2007
Biotechnology Start-up Nuon Therapeutics Inc. Completes $5 Million Series A Financing and Names Management Team
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 19 Jul 2007
Elan and Biogen Idec Preparing to Appeal Ruling on European Application for Natalizumab for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 18 Jul 2007
Pivotal CIMZIA(TM) Data in Crohn's Disease Published in New England Journal of Medicine
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 10 Jul 2007
ACTEMRA(TM) (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 19 Jun 2007
HealthSonix to Launch Combination Therapy Program With a Major Pharmaceutical Company for Patients with Advanced Rheumatoid Arthritis
Devices
 HSMN NewsFeed - 15 Jun 2007
Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia(R) (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
Biopharmaceuticals
 HSMN NewsFeed - 15 Jun 2007
REMICADE(R) Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation
Biopharmaceuticals
 HSMN NewsFeed - 15 Jun 2007
Three Studies Suggest Abbott's HUMIRA(R) (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 14 Jun 2007
CIMZIA(TM) Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 13 Jun 2007
Logical Therapeutics Inc. Raises US $30M Series B to Advance Drug Pipeline Targeting Inflammatory Diseases
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 13 Jun 2007
Latest Data Show MabThera(R) Provides Significant and Sustained Relief From Signs and Symptoms of Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 7 Jun 2007
Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 7 Jun 2007
Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 4 Jun 2007
GenVec Announces Update of Safety and Efficacy Data from Pivotal Phase II/III PACT Study of TNFerade(TM) at ASCO
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2007
Ception Therapeutics Raises Additional $14.7 Million Bringing Total Series C Financing to $77 Million
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 29 May 2007
Elan and Biogen Idec Announce a FDA Advisory Committee Meeting to Review TYSABRI(R) for the Treatment of Crohn's Disease
Biopharmacetuicals Gastroenterology FDA
 HSMN NewsFeed - 22 May 2007
New Analysis of Data Shows Treatment With Abbott's HUMIRA(R) (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 22 May 2007
UCB Presents Long-Term CIMZIA(TM) Data in Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 7 May 2007
Abbott Seeks U.S. and E.U. Regulatory Approvals for HUMIRA(R) (Adalimumab) as a Treatment for Juvenile Rheumatoid Arthritis
Biopharmaceuticals FDA Regulatory
 HSMN NewsFeed - 4 May 2007
Royalty Pharma Acquires a Portion of New York University's Royalty Interest in Remicade(R) for $650 Million
Biopharmaceuticals
 HSMN NewsFeed - 4 May 2007
Abbott's Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 27 Apr 2007
Abbott's HUMIRA(R) (Adalimumab) Receives Positive Opinion from European Medicines Agency for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 14 Apr 2007
ARIAD files claim against Amgen and Wyeth Alleging Infringement of NF-(kappa)B Patent by Enbrel(R) and Kineret(R)
Biopharmaceuticals Litigation
 HSMN NewsFeed - 10 Apr 2007
Abbott Opens New Biotechnology Manufacturing Facility in Puerto Rico
Biopharmaceuticals
 HSMN NewsFeed - 4 Apr 2007
Protemix Raises US$14.5 Million in First Close of Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 2 Apr 2007
Abbott Seeks U.S. and E.U. Regulatory Approval for HUMIRA(R) (Adalimumab) in Psoriasis
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 27 Mar 2007
MediciNova Announces Positive Clinical Results From MN-166 Phase II Multiple Sclerosis Trial
Biopharmaceuticals Neurology
 HSMN NewsFeed - 26 Mar 2007
European Union CHMP Recommends Approval of First and Only Biologic Treatment for Pediatric Crohn's Disease: REMICADE(R)
Biopharmaceuticals Regulatory Gastroenterology
 HSMN NewsFeed - 23 Mar 2007
UCB Provides Update on CIMZIA(TM) for Crohn's Disease and Rheumatoid Arthritis in the US
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 14 Mar 2007
Tragara Pharmaceuticals, Inc. Announces Corporate Launch and Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 27 Feb 2007
HUMIRA(R) (Adalimumab) Receives FDA Approval For Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 23 Feb 2007
Significant Phase III Results with CIMZIA(TM) in Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 22 Feb 2007
Celera Presents Data Validating Its Metastasis Score as a Molecular Prognostic Tool in Breast Cancer
Diagnostics Oncology
 HSMN NewsFeed - 20 Feb 2007
MedImmune Further Expands its Commercial Organization Expertise With Appointment of Two Additional Vice Presidents
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Feb 2007
Targeted Genetics Provides Inflammatory Arthritis Clinical Trial Update
Biopharmaceuticals
 HSMN NewsFeed - 2 Feb 2007
Psoriasis Patients Show Significant Improvement in Symptoms with Abbott's HUMIRA(R) in New Phase III Study
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 2 Feb 2007
New Analyses Reinforce Efficacy of REMICADE(R) in Treatment of Severe Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 2 Feb 2007
REMICADE(R) Therapy Shown to Improve Productivity in Patients Treated for Chronic Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 30 Jan 2007
Ception Therapeutics Raises $63 Million in Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 26 Jan 2007
GenVec Announces First Patient Treated with TNFerade(TM) for Head and Neck Cancer at University of Chicago
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jan 2007
GenVec Receives Clearance From FDA for EUS Administration of TNFerade(TM)
Biopharmaceuticals Oncology FDA Drug Delivery
 HSMN NewsFeed - 8 Jan 2007
Osiris Therapeutics Receives FDA Fast Track Status for Its Crohn's Disease Stem Cell Therapy and Clearance to Start Phase III Clinical Trial
Regenerative Medicine Gastroenterology
 HSMN NewsFeed - 22 Dec 2006
UCB Announces Positive Results From Two New Phase III Studies in Rheumatoid Arthritis and Provides Update on the Status of US Approval for CIMZIATM in the Treatment of Crohn's Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Dec 2006
GenVec Announces Efficacy Update in Phase II/III Clinical Trial of TNFerade(TM) in Locally Advanced Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Dec 2006
GenVec Announces Completion of Interim Safety Data Analysis for Phase II/III Trial with TNFerade(TM) in Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2006
Osiris Therapeutics Provides Update on Phase II Trial Evaluating PROCHYMAL(TM) for the Treatment of Acute Graft vs. Host Disease
Biopharmaceuticals
 HSMN NewsFeed - 14 Nov 2006
ORENCIA(R) (abatacept) or REMICADE(R)(infliximab) Demonstrated Superior Efficacy to Placebo at Six Months With ORENCIA Demonstrating Both Durable Efficacy and a More Favorable Safety Profile Through 12 Months
Biopharmaceuticals
 HSMN NewsFeed - 14 Nov 2006
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval for Inhibiting Structural Joint Damage and Improving Physical Function in Patients With Psoriatic Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Nov 2006
ORENCIA(R) (abatacept) Data Demonstrated Improvement in Children and Adolescents With Juvenile Idiopathic Arthritis as Measured by the Validated ACR Pediatric Criteria
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2006
Data Shows ENBREL Provides Sustained Clinical Improvements for People with Ankylosing Spondylitis for up to Three Years
Biopharmaceuticals
 HSMN NewsFeed - 12 Nov 2006
ENBREL is the First Biologic to Publish Data Showing Safety and Sustained Efficacy for up to Nine Years in Patients with Moderate-to-Severe Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 9 Nov 2006
Two-Year Data for ORENCIA(R) (abatacept) Demonstrate Continued Efficacy in Adults With Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 9 Nov 2006
Osiris Therapeutics Reports Positive Phase II Results Using PROCHYMAL(TM) for the Treatment of Acute Graft vs. Host Disease
Biopharmaceuticals Regenerative Medicine
 HSMN NewsFeed - 26 Oct 2006
Abbott's HUMIRA(R) (Adalimumab) Granted FDA Priority Review for the Treatment of Moderately to Severely Active Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 26 Oct 2006
Royalty Pharma Announces Agreement Regarding the Purchase of the Rights to a Pre-Existing Royalty Interest in HUMIRA(R) From AstraZeneca and CAT
Biopharmaceuticals
 HSMN NewsFeed - 24 Oct 2006
TYSABRI(R) Maintained Remission in Patients with Moderate-to-Severe Crohn's Disease Treated for Longer Than Two Years According to Data Presented This Week
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
New Data Show CIMZIA(TM) (certolizumab pegol) May Improve Productivity in Work and with Daily Activities for People with Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
New Phase III Data Shows Abbott's HUMIRA(R) (Adalimumab) Induced Clinical Remission In Patients With Crohn's Disease Who Lost Response to, or Were Intolerant to, Remicade(R) (Infliximab)
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
New Analysis Shows CIMZIA(TM) (Certolizumab Pegol) Maintained Remission and Response in Recent Onset Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
New Efficacy Data Show CIMZIA(TM) (Certolizumab Pegol) Maintained Response and Remission in Crohn's Patients Previously Treated With Infliximab
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
Data Show Treatment With Remicade(R) Reduced Hospitalizations for Ulcerative Colitis Patients By Half
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 Oct 2006
FDA Expands REMICADE(R) Indication for Ulcerative Colitis: Biologic Maintains Long-Term Clinical Remission and Mucosal Healing
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 17 Oct 2006
Paul Strauss, M.D. Joins Omeros as VP, Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Oct 2006
Hollis-Eden Pharmaceuticals Presents New Clinical Data That Support Use of NEUMUNE in Mitigating Acute Radiation Syndrome and Healthcare-Associated Infections
Biopharmaceuticals
 HSMN NewsFeed - 5 Oct 2006
New Phase III Data Show Abbott's HUMIRA(R) (Adalimumab) Was Statistically Superior to Methotrexate in Patients With Psoriasis
Biopharmaceuticals
 HSMN NewsFeed - 29 Sep 2006
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Sep 2006
FDA Approves REMICADE(R) for Treatment of Chronic Severe Plaque Psoriasis: Marks Major Milestone for Patients With High Disease Burden
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Sep 2006
Stelios Papadopoulos to Resign from GenVec's Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Sep 2006
Abbott Submits U.S. and E.U. Regulatory Applications Seeking Approval for HUMIRA(R) (Adalimumab) as a Treatment for Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 27 Jun 2006
New Research Findings Published in National Academy of Sciences Journal Show Unique Promise of ONCONASE in the Prevention and Treatment of Mesothelioma and Lung Cancer Caused by Asbestos
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jun 2006
Abbott Receives FDA Approval for New HUMIRA(R) Delivery Device
Biopharmaceuticals FDA Drug Delivery
 HSMN NewsFeed - 23 Jun 2006
New Phase III Data Demonstrate That Abbott's HUMIRA(R) (Adalimumab) Sustained Reduction in Signs and Symptoms Through One Year in Patients With Ankylosing Spondylitis
Biopharmaceuticals
 HSMN NewsFeed - 22 Jun 2006
Analysis of Phase III Study Showed Rituxan(R) Plus Methotrexate Reduced Joint Damage in Rheumatoid Arthritis Patients Who Respond Inadequately to TNF Antagonist Therapies
Biopharmaceuticals
 HSMN NewsFeed - 22 Jun 2006
Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the European Rheumatology Meeting
Biopharmaceuticals
 HSMN NewsFeed - 24 May 2006
Ocera Therapeutics Initiates Phase 3 Trial in Fistulizing Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 24 May 2006
New Analysis Showed Ulcerative Colitis Patients in Clinical Remission Had Higher Rates of Employment and Lower Rates of Disability
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 May 2006
Long-Term Results from TNFerade(TM) Pancreatic Cancer Study and Updated Survival Results from TNFerade(TM) Esophageal Cancer Study Both Reported at Digestive Disease Week
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2006
New CIMZIA (TM) Data from PRECiSE Program Reinforce Robust Efficacy in Once-Monthly Treatment of Crohn's Disease and Consistent Tolerability Profile
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 22 May 2006
Promising Pivotal Phase III Data Show Abbott's Humira(R) (Adalimumab) Maintained Clinical Remission in Patients With Crohn's Disease Through One Year
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 5 May 2006
U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) Supplemental Biologics License Application (sBLA) for Third-Party Manufacturing Facility Lonza Biologics Inc.
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 227

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 227 additional stories matching:
TNF
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!